Questions discussed in this category

It used to be a contraindication for G-CSF use for AML patients, but currently, several protocols include it to decrease neutropenic duration.

Many patients have had prior chemotherapy exposure with newly diagnosed AML that may not have classic therapy-related cytogenetics.  How do you a...

I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

Should the goal always be to proceed to a second transplant? 

Papers discussed in this category

Fertil. Steril., 2013 Sep 05

Cell stem cell, 2017-09-07


Blood, 2019-01-03

Leukemia, 2019 Oct 18

N. Engl. J. Med.,

Nature medicine, 2015-02

Pediatric blood & cancer, 2014-03

Clin Lymphoma Myeloma Leuk, 2017 Mar 07

J Clin Oncol, 2020 May 13

American journal of hematology, 2019-07

Pediatr Blood Cancer, 2018 Jun 12

British journal of haematology, 2011-11

Haematologica, 2020 Feb 6

Blood, 2013-05-02

Cochrane Database Syst Rev, 2012 Jun 13

N Engl J Med,

Blood, 2006 Sep 28

J Clin Oncol, 2010 Apr 20

J Clin Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-12-20

Clin Infect Dis,